Neximmune announces ind clearance by the us fda for nexi-003 for the treatment of hpv-related cancers

Gaithersburg, md., july 14, 2022 (globe newswire) -- neximmune, inc. (nasdaq: nexi), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific t cells, has received ind clearance for the company's first cellular therapy product candidate addressing solid tumors.  nexi-003, an autologous antigen-specific t cell product (cd3+/cd4-), is being developed for patients with relapsed or refractory human papillomavirus (hpv)-related cancers.
NEXI Ratings Summary
NEXI Quant Ranking